Wei-Mi-Shu Decoction ameliorates gastric mucosal injury in chronic gastritis with liver-stomach disharmony syndrome through the gut microbiota-hepatic bile acid metabolism axis
Frontiers in Pharmacology · 30.10.2026 · 17
DOI: 10.3389/fphar.2026.1983808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.10.2026. Verfasst von Xiaoyun Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical College, Qinghai University, Xining, China. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Chronic gastritis (CG) is a high‐incidence disease in the digestive system, and liverstomach disharmony syndrome (LSD) is a relatively common syndrome type. This study aimed to evaluate the role and possible mechanism of traditional Chinese medicine Wei‐Mi‐Shu Decoction (WMS) in treating LSDCG.
Methods
The CG and LSDCG animal models were established and treated with WMS to observe the TCM syndrome scores and behavioral changes, histopathological alterations of the gastric mucosa, and expressions of pro‐inflammatory cytokines and tight junction proteins. Then, the changes of gut microbiota and bile acids (BAs) were analyzed by microbiota sequencing and mass spectrometry, and the protein expressions of BA receptors were detected by immunohistochemistry and WB. Finally, Lgr5‐positive (Lgr5 + ) gastric cells were observed by immunofluorescence staining, the expression of gastric mucosal cell differentiation markers was detected by RT‐qPCR, and the fatty acid oxidation (FAO) of Lgr5 + cells was observed by fluorescence double staining.
Results
WMS reduced the TCM syndrome scores, increased the autonomous activity ability, and improved gastric mucosal injury, inflammatory response, and gastric mucosal barrier disruption in the CG and LSDCG model rats. WMS also regulated the intestinal microbiota and BA metabolism of model rats, and promoted the levels of PPARα and RXR. In addition, WMS attenuated the loss of Lgr5 + gastric stem cells and promoted their differentiation and FAO.
Conclusion
In conclusion, WMS promoted the differentiation of Lgr5 + gastric stem cells, potentially involving the gut microbiotahepatic BA metabolism axis to repair gastric mucosal injury in LSDCG.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical College, Qinghai University, Xining, China.
- Department of Hepatopathy, Qinghai Provincial Hospital of Traditional Chinese Medicine, Xining, China.
- Department of Research Institute of Traditional Chinese Medicine, Qinghai Provincial Hospital of Traditional Chinese Medicine, Xining, China.
- Department of Cardiology, Qinghai Provincial Hospital of Traditional Chinese Medicine, Xining, China.
- Department of Pharmacy, Qinghai Provincial Hospital of Traditional Chinese Medicine, Xining, China.
- Department of Spleen and Stomach Diseases, Qinghai Provincial Hospital of Traditional Chinese Medicine, Xining, China.
Zitieren
APA
Zou, X., Jia, S., Wei, M., Qi, Y., Li, H., Liu, Y., & Li, J. (2026). Wei-Mi-Shu Decoction ameliorates gastric mucosal injury in chronic gastritis with liver-stomach disharmony syndrome through the gut microbiota-hepatic bile acid metabolism axis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1983808
Vancouver
Zou X, Jia S, Wei M, Qi Y, Li H, Liu Y, et al. Wei-Mi-Shu Decoction ameliorates gastric mucosal injury in chronic gastritis with liver-stomach disharmony syndrome through the gut microbiota-hepatic bile acid metabolism axis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1983808
BibTeX
@article{Zou2026,
author = {Zou, Xiaoyun and Jia, Shouning and Wei, Minmin and Qi, Yongfu and Li, Hailing and Liu, Yan and Li, Junru},
title = {Wei-Mi-Shu Decoction ameliorates gastric mucosal injury in chronic gastritis with liver-stomach disharmony syndrome through the gut microbiota-hepatic bile acid metabolism axis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1983808}
}
EUVIMED